Drugs / AAV RPE65
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02781480 | Apr 2016 → Dec 2018 | Leber congenital amaurosis | MeiraGTx UK II Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAV RPE65 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02781480 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “AAV2/5 vector” NCT02781480 ↗ |
| Route | Other | “Subretinal administration of a single low dose of range AAV-RPE65” NCT02781480 ↗ |